qiagen nv - QGEN

QGEN

Close Chg Chg %
41.52 0.09 0.22%

Open Market

41.61

+0.09 (0.22%)

Volume: 240.89K

Last Updated:

Apr 16, 2025, 10:05 AM EDT

Company Overview: qiagen nv - QGEN

QGEN Key Data

Open

$41.79

Day Range

41.35 - 41.80

52 Week Range

37.63 - 49.29

Market Cap

$8.98B

Shares Outstanding

216.12M

Public Float

214.41M

Beta

0.62

Rev. Per Employee

N/A

P/E Ratio

108.55

EPS

$0.38

Yield

0.00%

Dividend

$1.26

EX-DIVIDEND DATE

Jan 29, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

1.41M

 

QGEN Performance

1 Week
 
-1.07%
 
1 Month
 
5.19%
 
3 Months
 
-12.23%
 
1 Year
 
0.94%
 
5 Years
 
-3.44%
 

QGEN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 23
Full Ratings ➔

About qiagen nv - QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

QGEN At a Glance

QIAGEN NV
Hulsterweg 82
Venlo, Limburg 5912 PL
Phone 31-77-355-66-00 Revenue 1.98B
Industry Medical Specialties Net Income 83.59M
Sector Health Technology 2024 Sales Growth 0.657%
Fiscal Year-end 12 / 2025 Employees 5,765
View SEC Filings

QGEN Valuation

P/E Current 108.547
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 119.713
Price to Sales Ratio 5.058
Price to Book Ratio 2.775
Price to Cash Flow Ratio 14.857
Enterprise Value to EBITDA 14.846
Enterprise Value to Sales 5.24
Total Debt to Enterprise Value 0.146

QGEN Efficiency

Revenue/Employee 343,142.064
Income Per Employee 14,499.74
Receivables Turnover 4.31
Total Asset Turnover 0.335

QGEN Liquidity

Current Ratio 3.605
Quick Ratio 3.091
Cash Ratio 2.121

QGEN Profitability

Gross Margin 63.33
Operating Margin 25.02
Pretax Margin 6.124
Net Margin 4.226
Return on Assets 1.416
Return on Equity 2.267
Return on Total Capital 1.646
Return on Invested Capital 1.704

QGEN Capital Structure

Total Debt to Total Equity 42.40
Total Debt to Total Capital 29.775
Total Debt to Total Assets 26.584
Long-Term Debt to Equity 40.218
Long-Term Debt to Total Capital 28.243
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Qiagen Nv - QGEN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.25B 2.14B 1.97B 1.98B
Sales Growth
+20.39% -4.89% -8.23% +0.66%
Cost of Goods Sold (COGS) incl D&A
819.38M 771.49M 742.39M 725.40M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
214.93M 208.40M 205.34M 203.27M
Depreciation
129.27M 133.38M 130.37M 135.13M
Amortization of Intangibles
85.66M 75.01M 74.96M 68.14M
COGS Growth
+24.44% -5.85% -3.77% -2.29%
Gross Income
1.43B 1.37B 1.22B 1.25B
Gross Income Growth
+18.18% -4.35% -10.74% +2.44%
Gross Profit Margin
+63.61% +63.97% +62.23% +63.33%
2021 2022 2023 2024 5-year trend
SG&A Expense
774.43M 793.80M 777.68M 757.86M
Research & Development
189.96M 189.86M 198.51M 193.49M
Other SG&A
584.47M 603.95M 579.17M 564.36M
SGA Growth
+14.83% +2.50% -2.03% -2.55%
Other Operating Expense
- - - -
-
Unusual Expense
13.16M (28.30M) 47.33M 405.57M
EBIT after Unusual Expense
644.69M 604.53M 397.92M 89.38M
Non Operating Income/Expense
35.62M (33.57M) 85.30M 75.61M
Non-Operating Interest Income
9.55M 32.76M 78.99M 68.02M
Equity in Earnings of Affiliates
12.00M 3.80M 4.20M 5.72M
Interest Expense
54.48M 58.36M 53.41M 43.84M
Interest Expense Growth
-23.61% +7.12% -8.48% -17.92%
Gross Interest Expense
54.48M 58.36M 53.41M 43.84M
Interest Capitalized
- - - -
-
Pretax Income
625.83M 512.60M 429.81M 121.15M
Pretax Income Growth
+42.41% -18.09% -16.15% -71.81%
Pretax Margin
+27.79% +23.94% +21.87% +6.12%
Income Tax
113.23M 89.39M 88.51M 37.56M
Income Tax - Current - Domestic
1.71M 9.67M 11.39M 14.35M
Income Tax - Current - Foreign
116.81M 89.32M 66.38M 46.25M
Income Tax - Deferred - Domestic
(1.78M) (683.00K) (5.54M) 9.14M
Income Tax - Deferred - Foreign
(3.51M) (8.92M) 16.27M (32.18M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
12.00M 3.80M 4.20M 5.72M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
512.60M 423.21M 341.30M 83.59M
Minority Interest Expense
- - - -
-
Net Income
512.60M 423.21M 341.30M 83.59M
Net Income Growth
+42.71% -17.44% -19.35% -75.51%
Net Margin Growth
+22.77% +19.76% +17.37% +4.23%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
512.60M 423.21M 341.30M 83.59M
Preferred Dividends
- - - -
-
Net Income Available to Common
512.60M 423.21M 341.30M 83.59M
EPS (Basic)
2.3842 1.9719 1.5863 0.3862
EPS (Basic) Growth
+42.99% -17.29% -19.55% -75.65%
Basic Shares Outstanding
215.00M 214.62M 215.15M 216.44M
EPS (Diluted)
2.3425 1.95 1.5693 0.3826
EPS (Diluted) Growth
+44.05% -16.76% -19.52% -75.62%
Diluted Shares Outstanding
218.82M 217.03M 217.49M 218.47M
EBITDA
872.78M 784.63M 650.58M 698.23M
EBITDA Growth
+21.34% -10.10% -17.08% +7.32%
EBITDA Margin
+38.76% +36.64% +33.10% +35.30%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 49.122
Number of Ratings 23 Current Quarters Estimate 0.563
FY Report Date 06 / 2025 Current Year's Estimate 2.279
Last Quarter’s Earnings 0.49 Median PE on CY Estimate N/A
Year Ago Earnings 2.24 Next Fiscal Year Estimate 2.474
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 20 20
Mean Estimate 0.56 0.59 2.28 2.47
High Estimates 0.57 0.60 2.36 2.55
Low Estimate 0.54 0.56 2.25 2.38
Coefficient of Variance 1.85 1.85 1.46 2.25

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 11
OVERWEIGHT 1 1 2
HOLD 11 10 9
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Qiagen Nv - QGEN

Date Name Shares Transaction Value
Jul 18, 2024 Roland Sackers N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 18, 2024 Roland Sackers N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 18, 2024 Thierry Bernard N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 18, 2024 Thierry Bernard N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Qiagen Nv in the News